High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis

JAMA

Volumn 290, Issue 17, 2003, Pages 2322-2324

  Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; RECOMBINANT APOLIPOPROTEIN A1; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0242493614     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.17.2322     Document Type: Editorial

References (25)

1. Barter P, Kastelein J, Nunn A, Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003;168:195-211.
2. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol. 2002;90:62i-70i.
3. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, II. Circulation. 2001;104:2376-2383.
4. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, II. Circulation. 2001;104:2498-2502.
5. Reichert JM, Paquette C. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. Curr Opin Mol Ther. 2003;5:139-147.
6. Miyazaki A, Sakuma S, Morikawa W, et al. Intravenous injection of rabbot apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1882-1888.
7. Nanje MN, Crouse JR, King JM, et al. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol. 1996;16:1203-1214.
8. Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. A-IMilano apoprotein: decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
9. Roma P, Gregg RE, Meng MS, et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest. 1993;91:1445-1452.
10. Gualandri V, Franceschini G, Sirtori CR, et al. Al Milano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083-1097.
11. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant. Circulation. 2001;103:1949-1954.
12. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 1997;38:191-205.
13. Rader DJ, Ikewaki K, Duverger N, et al. Very low high-density lipoproteins without coronary atherosclerosis. Lancet. 1993;342:1455-1458.
14. Chiesa G, Sirtori CR. Recombinant apolipoprotein A-I (Milano): a novel agent for the induction of regression of atherosclerotic plaques. Ann Med. 2003;35:267-273.
15. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
16. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol. 2003;92:42J-49J.
17. Zhang Y, Zanotti I, Reilly M, Glick JM, Rothblat GH, Rader DJ. Overexpression of apoA-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661-663.
18. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans. Circulation. 1999;100:594-598.
19. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
20. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
21. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.
22. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1243.
23. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100:1816-1822.
24. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
25. Young SG, Fielding CJ. The ABCs of cholesterol efflux. Nat Genet. 1999;22:316-318.